Hansen A, Dörner T
Park-Klinik Weissensee, Akademisches Lehrkrankenhaus der Charité, Schönstr. 80, 13086 Berlin.
Z Rheumatol. 2010 Feb;69(1):19-24. doi: 10.1007/s00393-009-0515-6.
Sjögren's syndrome is a systemic inflammatory-rheumatic disorder of hitherto unknown origin and, hence, adequate therapy options are not available in most cases. Treatment of sicca symptoms in Sjögren's patients is primarily symptomatic. Glucocorticoids, NSAIDs and/or immunosuppressive drugs may be used for the treatment of extraglandular manifestations or complications. Although there have been few clinical studies to date, new insights into the pathogenesis of this disorder may permit novel therapeutic strategies. Targeting B-cell candidates as a new therapeutic option in this entity has shown promising results. B-cell-depletion using Rituximab has been tested in initial clinical trials for the treatment of Sjögren patients, both with and without associated B-cell non-Hodgkin-lymphoma; however, further studies as well as reliable outcome criteria are needed. Further therapeutic options are currently in development or early clinical testing.
干燥综合征是一种病因不明的系统性炎症性风湿性疾病，因此在大多数情况下没有足够的治疗选择。干燥综合征患者的口干症状治疗主要是对症治疗。糖皮质激素、非甾体抗炎药和/或免疫抑制药物可用于治疗腺外表现或并发症。尽管迄今为止临床研究较少，但对该疾病发病机制的新见解可能会带来新的治疗策略。将B细胞作为该疾病新的治疗选择已显示出有前景的结果。使用利妥昔单抗进行B细胞清除已在治疗干燥综合征患者的初步临床试验中进行了测试，这些患者伴有或不伴有相关的B细胞非霍奇金淋巴瘤；然而，还需要进一步的研究以及可靠的疗效标准。目前正在开发或进行早期临床试验的其他治疗选择。
